Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Clinical trial NCT04648475 · UNKNOWN
Trial details
- NCT number
- NCT04648475
- Sponsor
- Chongqing Precision Biotech Co., Ltd
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-25
- Primary completion
- 2023-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.